Outcomes following transcatheter aortic valve replacement in the United States

JAMA

Volumn 310, Issue 19, 2013, Pages 2069-2077

  Mack, Michael J ^a   Brennan, J Matthew ^b   Brindis, Ralph ^c   Carroll, John ^d   Edwards, Fred ^e   Grover, Fred ^d   Shahian, David ^f   Tuzcu, E Murat ^g   Peterson, Eric D ^b   Rumsfeld, John S ^d   Hewitt, Kathleen ^h   Shewan, Cynthia ⁱ   Michaels, Joan ^h   Christensen, Barb ^h   Christian, Alexander ^b   O'Brien, Sean ^b   Holmes, David ^j  

^a THE HEART HOSPITAL BAYLOR PLANO   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

^h AMERICAN COLLEGE OF CARDIOLOGY   (United States)

ⁱ Society of Thoracic Surgeons   (United States)

^j MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE KIDNEY FAILURE; AGED; AORTA STENOSIS; ARTICLE; BLOOD VESSEL INJURY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INCIDENCE; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MORTALITY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PATIENT SELECTION; PERCUTANEOUS AORTIC VALVE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURGICAL APPROACH; SURGICAL RISK; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT INDICATION; UNITED STATES; VASCULAR ACCESS;

EID: 84887950245     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282043     Document Type: Article

References (23)

1. Department of Health and Human Services. Correspondence regarding premarket approval application for Edwards Sapien transcatheter heart valve. November 2, 2011. http://www.accessdata.fda.gov/cdrh-docs/pdf10/p100041a.pdf. Accessed October 28, 2013.
2. US Food and Drug Administration. FDA expands approved use of Sapien artificial heart valve. October 19, 2012. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm323478.htm. Accessed October 28, 2013.
3. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for transcatheter aortic valve replacement. http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId= 355&ncdver=1&NCAId=257&ver=4&NcaName= Transcatheter+Aortic+Valve+Replacement+%28TAVR%29&bc= ACAAAAAACAAAAA%3D%3D&. Accessed November 1, 2013.
4. Carroll JD, Edwards FH, Marinac-Dabic D, et al. The STS-ACC transcatheter valve therapy national registry: a new partnership and infrastructure for the introduction and surveillance of medical devices and therapies. J Am Coll Cardiol. 2013;62(11):1026-1034.
5. Leon MB, Smith CR, Mack M, et al PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597-1607.
6. Smith CR, Leon MB, Mack MJ, et al PARTNER Trial Investigators. Transcatheter vs surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187-2198.
7. American College of Cardiology; Society of Thoracic Surgeons. ACC/STS TVT Registry home page. https://www.ncdr.com/TVT/Home/Default.aspx. Accessed October 28, 2013.
8. American College of Cardiology; Society of Thoracic Surgeons. ACC/STS TVT Registry: data collection. https://www.ncdr.com/tvt/Home/DataCollection.aspx. Accessed October 28, 2013.
9. American College of Cardiology; Society of Thoracic Surgeons. ACC/STS TVT Registry: NCDR participants/site manager contact. https://www.ncdr.com/TVT/ Private/Resources/ParticipantDirectory.aspx. Accessed October 28, 2013.
10. Society of Thoracic Surgeons. Online STS risk calculator. http://riskcalc.sts.org/STSWebRiskCalc273/. Accessed October 28, 2013.
11. Wilson CM, Kostsuca SR, Boura JA. Utilization of a 5-meter walk test in evaluating self-selected gait speed during preoperative screening of patients scheduled for cardiac surgery. Cardiopulm Phys Ther J. 2013;24(3):36-43.
12. Garin O, Herdman M, Vilaqut G, et al. Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures [published online May 17, 2013]. Heart Fail Rev. doi:10.1007/s10741-013-9394-7.
13. Leon MB, Piazza N, Nikolsky E, et al. Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. J Am Coll Cardiol. 2011;57(3):253-269.
14. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60(15):1438-1454.
15. US Food and Drug Administration. Strengthening Our National System for Medical Device Postmarket Surveillance. September 2012. http://www.fda.gov/ downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM301924.pdf. Accessed October 28, 2013.
16. Resnic FS, Normand SL. Postmarketing surveillance of medical devices - filling in the gaps. N Engl J Med. 2012;366(10):875-877.
17. Hauser RG. Here we go again - failure of postmarketing device surveillance. N Engl J Med. 2012;366(10):873-875.
18. Rumsfeld JS, Peterson ED. Achieving meaningful device surveillance: from reaction to proaction. JAMA. 2010;304(18):2065-2066.
19. Gilard M, Eltchaninoff H, Iung B, et al; FRANCE 2 Investigators. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med. 2012;366(18):1705-1715.
20. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the Sapien Aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards Sapien valve. Circulation. 2010;122(1):62-69.
21. Hamm CW, Möllmann H, Holzhey D, et al GARY Executive Board. The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J. 2013. doi:10.1093/eurheart/eht381.
22. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes after transcatheter aortic valve implantation in high-risk patients with severe aortic stenosis: the UK TAVI (United Kingdom Transcatheter Aortic Valve Implantation) Registry. J Am Coll Cardiol. 2011;58(20):2130-2138.
23. Cardiac Interventions Today. FDA approves revised labeling to allow alternative access sites for Edwards Sapien TAVR device. September 23, 2013. http://www.bmctoday.net/citoday/2013/08/article.asp?f=fda-approves-revised- labeling-to-allow-alternative-access-sites-for-edwards-sapien-tavr-device. Accessed October 28, 2013.